- Home
- WOLF vs DYN Comparison
WOLF vs DYN Comparison
Compare WOLF & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- DYN
- Stock Information
- Founded
- WOLF 1987
- DYN 1984
- Country
- WOLF United States
- DYN United States
- Employees
- WOLF N/A
- DYN N/A
- Industry
- WOLF Semiconductors
- DYN Medicinal Chemicals and Botanical Products
- Sector
- WOLF Technology
- DYN Health Care
- Exchange
- WOLF Nasdaq
- DYN Nasdaq
- Market Cap
- WOLF 978.5M
- DYN 848.8M
- IPO Year
- WOLF 1993
- DYN 2020
- Fundamental
- Price
- WOLF $3.28
- DYN $11.41
- Analyst Decision
- WOLF Hold
- DYN Strong Buy
- Analyst Count
- WOLF 14
- DYN 12
- Target Price
- WOLF $10.67
- DYN $47.00
- AVG Volume (30 Days)
- WOLF 30.2M
- DYN 2.9M
- Earning Date
- WOLF 05-08-2025
- DYN 05-08-2025
- Dividend Yield
- WOLF N/A
- DYN N/A
- EPS Growth
- WOLF N/A
- DYN N/A
- EPS
- WOLF N/A
- DYN N/A
- Revenue
- WOLF $761,300,000.00
- DYN N/A
- Revenue This Year
- WOLF N/A
- DYN N/A
- Revenue Next Year
- WOLF $26.83
- DYN N/A
- P/E Ratio
- WOLF N/A
- DYN N/A
- Revenue Growth
- WOLF N/A
- DYN N/A
- 52 Week Low
- WOLF $2.06
- DYN $6.36
- 52 Week High
- WOLF $30.86
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- WOLF 46.23
- DYN 55.69
- Support Level
- WOLF $3.22
- DYN $9.17
- Resistance Level
- WOLF $4.60
- DYN $12.47
- Average True Range (ATR)
- WOLF 0.51
- DYN 0.96
- MACD
- WOLF 0.15
- DYN 0.13
- Stochastic Oscillator
- WOLF 36.61
- DYN 67.88
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.